NYSE:CYBN Cybin (CYBN) Stock Price, News & Analysis $7.60 -0.15 (-1.87%) As of 02:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Cybin Stock (NYSE:CYBN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cybin alerts:Sign Up Key Stats Today's Range$7.44▼$7.9150-Day Range$7.01▼$9.0052-Week Range$4.81▼$13.88Volume249,122 shsAverage Volume315,249 shsMarket Capitalization$179.17 millionP/E RatioN/ADividend YieldN/APrice Target$85.00Consensus RatingBuy Company Overview Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada. Read More Cybin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCYBN MarketRank™: Cybin scored higher than 55% of companies evaluated by MarketBeat, and ranked 534th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCybin has only been the subject of 2 research reports in the past 90 days.Read more about Cybin's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($4.76) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CYBN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CYBN. News and Social Media3.0 / 5News Sentiment0.34 News SentimentCybin has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cybin this week, compared to 1 article on an average week.Search Interest19 people have searched for CYBN on MarketBeat in the last 30 days. This is an increase of 138% compared to the previous 30 days.MarketBeat Follows22 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 340% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.94% of the stock of Cybin is held by institutions.Read more about Cybin's insider trading history. Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address CYBN Stock News Headlines3 High-Risk, High-Reward Stocks With Explosive Upside (CYBN)Rezolve, Aurora, and Cybin are 2025's top growth stocks in AI, driverless trucks, and psychedelics, with huge upside potential and key catalysts unfolding.July 16, 2025 | marketbeat.comCybin Inc. Schedules Virtual Annual General Meeting for August 2025July 28 at 4:47 PM | msn.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 29 at 2:00 AM | Priority Gold (Ad)Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderJuly 17, 2025 | businesswire.comCYBN - Cybin Inc Ordinary Shares Ownership - MorningstarJuly 2, 2025 | morningstar.comMREPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible DebenturesJuly 1, 2025 | businesswire.comCybin Reports Fiscal Year 2025 Financial Results and Recent Business HighlightsJune 30, 2025 | businesswire.comCybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible DebenturesJune 30, 2025 | businesswire.comSee More Headlines CYBN Stock Analysis - Frequently Asked Questions How have CYBN shares performed this year? Cybin's stock was trading at $8.82 at the start of the year. Since then, CYBN stock has decreased by 15.3% and is now trading at $7.47. How were Cybin's earnings last quarter? Cybin Inc. (NYSE:CYBN) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cybin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), FuelCell Energy (FCEL), Meta Platforms (META), Aurora Cannabis (ACB), AlTi Global (ALTI), UiPath (PATH) and Tesla (TSLA). Company Calendar Last Earnings11/14/2023Today7/29/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:CYBN Previous SymbolNYSE:CYBN CIK1833141 Webwww.cybin.com Phone908-764-8385FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Cybin$85.00 High Price Target$150.00 Low Price Target$35.00 Potential Upside/Downside+1,027.2%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.58% Return on Assets-36.59% Debt Debt-to-Equity RatioN/A Current Ratio24.24 Quick Ratio24.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.83 per share Price / Book0.70Miscellaneous Outstanding Shares23,590,000Free Float17,962,000Market Cap$177.89 million OptionableNot Optionable Beta0.69 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NYSE:CYBN) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.